Breast Cancer and Estrogen

Determining the amount of estrogen act for breast cancer that a patient is producing, including their exposure to environmental estrogens, for both humans and animals, has been recognized in the medical world as being vitally important to health.
                                        
Besides identifying exposure to phytoestrogens and xenoestrogens, the medical profession believes the main source of estrogen act for breast cancer in females comes mainly from the ovaries, and in males from other tissues in their body that produce estradiol. There seems to be a lack of recognition by the medical profession that large amounts of adrenal estrogen may also be present, but are rarely measured.

As a practicing, clinical veterinarian, I have found elevated amounts of adrenal estrogen in over 100,000 canine, feline and equine females that had no ovarian tissue, and also in castrated males.

Approximately 1,000 human patients, whether male or female, also had elevated amounts of adrenal estrogen and act for breast cancer when tested by their physicians for a variety of different estrogenic induced, chronic, inflammatory diseases.
                                               
Total estrogen MUST be tested for every patient, whether human or animal. A total estrogen test is offered for humans by Quest Laboratories, LabCorp and possibly other human laboratories.

National Veterinary Diagnostic Laboratory is the only veterinary laboratory at this time that offers a total estrogen and act for breast cancer test for animals. To determine the amount of estrogen that is being produced by the inner layer adrenal cortex, simply measure the amounts of E1, E2 and E3 and total estrogen.

In male humans and animals, merely measure estradiol and total estrogen. In female humans and animals, patients without ovaries or patients that are postmenopausal, their E1, E2, E3 and total estrogen and act for breast cancer may be measured at any time.

If human females are still menstruating, it is best to determine their E1, E2, and E3 and total estrogen and act for breast cancer at the time their ovaries are the most quiescent, and tested once again at the time when their ovaries are the most active.

Read more

How is the Immune System Suppressed by Cancer

Direct Suppression/Inactivation of Oxygen Radicals:

Oxygen radicals from various different oxidases, including xanthine oxidase (XO) and NADPH oxidase (NADPHO) in macrophages and lymphocytes, as well as the circulation in the serum of XO, are responsible for the production of toxic substances such as peroxynitrite, OH radicals, hydrogen peroxide, etc. which are toxic to foreign proteins, bacteria, viruses, and cancer cells. This ability to produce large amounts of oxygen radicals is not seen in cancer cells themselves, but also in the cancer patients’ immune cells. They are weakened against cancer cell attack, partially because of the nitric oxide (NO) released by tumor cells.   Excellent work by Prof de Groot of Essen, indicated by adding exogenous xanthine oxidase ( XO) in hepatoma cells, hydrogen peroxide was produced to destroy the hepatoma cells. However, since XO is inhibited in cancer patients from NO generated by tumor cells and most likely other factors not yet known, the production of hydrogen peroxide that would normally destroy a cancer cell is not produced. NO from eNOS in cancer cells can travel through membranes and over long distances in the body. It has even been shown that cGMP is stimulated in the liver in colon cancer patients and this is most likely from growth factors and NO released from the tumor cells.  NO also is co linked to VEGF which in turn increases the antiapoptotic gene bcl-2. The other important influence of NO is in its inhibition of the proapoptoic caspases cascade. This in turn protects the cells from intracellular preprogrammed death.
                                           

One other important alteration by nitric oxide in immune suppression in relation to oxygen radicals is its inhibitory effect on the binding of leukocytes (PMN) at the endothelial surface. This is normally an early stage for toxicity against bacteria, or “foreign” substances. However, this inability of binding alters this form of toxicity too.

Inhibition of inducible Nitric Oxide Synthase (iNOS): In macrophages, leukocytes and T-killer cells, the production of a fast generated NO from iNOS causes a very fast reaction with superoxide radicals from oxidases. It is enhanced by free iron, and is responsible for the toxicity from these cells. One of these toxic products generated is peroxynitrite. When the iNOS is down regulated or inhibited, or the oxygen radicals totally suppressed, there is a tremendous reduction in toxicity to almost null in some cases.
                                    
Binding of iron also affects this toxicity. NO from the tumor cells actually suppresses the iNOS, and in addition it reduces oxygen radicals to stop the formation of peroxynitrite in these cells. But NO is not the only inhibitor of iNOS in cancer.

Read more

Biomarker panel to screen for pancreatic cancer may be possible

 

The growth of a very precise, blood-based pancreatic adenocarcinoma display that would be precise enough to analyze the common inhabitants for this dangerous condition may not be far out of arrive at, according to information provided at the Combined states Organization for Melanoma Research's Pancreatic Cancer: Advance and Difficulties meeting.
Matthew Firpo, Ph.D., a analysis associate teacher at the Huntsman Melanoma Institution at the School of Ut, came to the summary that testing a section of biomarkers might be effective by adopting the concept that pancreatic adenocarcinoma has wide inherited heterogeneity, significance no individual biomarker prevails that is associated with its analysis across the inhabitants of individuals who create the condition.

Although it is commonly approved that previously recognition of pancreatic adenocarcinoma would enhance success results, analysis initiatives up to now have been not successful at determining a biomarker or biomarker section that has a high analytic knowing.

"Any device that we set up in the common inhabitants to display for this condition would have to be very precise," Firpo described.

"Because this many forms of cancer is unusual, if everyone mature than age 50 in the Combined Declares was tested with a analyze that was only 95 % precise, we would have more than three thousand individuals each year with a bogus good recognition of pancreatic adenocarcinoma."

Therefore, Firpo said that any analyze for pancreatic adenocarcinoma implemented to the common inhabitants must have an precision of higher than 99 %. To see if such stages of precision were possible, the scientists calculated the stages of nine biomarkers of pancreatic adenocarcinoma in the system of 117 healthier control members, 58 members with serious pancreatitis and 159 sufferers with pancreatic adenocarcinoma.

Using a mathematical style, they established that many of these poor biomarkers existing in those sufferers with pancreatic adenocarcinoma had 95 % nature for the condition, but, on regular, only a 32 % knowing.

"Based on the information, and specifying 99 % nature, it would take a section of 40 biomarkers with 32 % regular knowing each and 95 % nature, of which seven biomarkers were above this tolerance," Firpo said.

The key to the research, according to Firpo, is recognizing the fact that pancreatic adenocarcinomas are genetically heterogeneous. By creating a style that made up the heterogeneity they were able to get over 99 % precision.

"Identifying 40 biomarkers is affordable. We believe we can find 40 biomarkers that are poor classifiers of the condition," he said. "That indicates that depending on the existing knowing of biomarkers that we have, there is wish for creating a section that would have higher than 99 % precision."

Read more

Metformin treatment caused cancer stem cell death in pancreatic cancer cell lines

 

Outcomes of some preclinical tests have shown that low amounts of the antidiabetic medication metformin may effectively eliminate melanoma control tissues, a group of tissues that are considered to be responsible for tumor start and, because they are immune to conventional chemotherapies, tumor backslide.

In addition, when metformin was along with a conventional radiation treatment used for pancreatic melanoma, the mixture therapy was able to effectively reduce both melanoma control tissues and more separated melanoma tissues, which form the volume of the tumor, according to information presented by Captain christopher Heeschen, M.D., Ph.D., at the American Organization for Many forms of cancer Research's Pancreatic Cancer: Progress and Difficulties meeting.

Heeschen is teacher for trial medicine at the Spanish National Many forms of cancer Analysis Center in The city, The country.

Most scientific studies of pancreatic melanoma performed during the last 15 decades have never show noticeable improvement in average success, indicating that the selected techniques were not sufficient for several reasons, according to Heeschen.

In the past few decades, scientists have determined melanoma control tissues which, versus the tissues of melanoma that make up the volume of the tumor, are a small part of tissues that are immune to conventional therapy.

"Therefore, effectively focusing on these tissues will be crucial for achieving higher cure rates in sufferers with pancreatic melanoma," he said. "Our newly growing information now indicate that metformin, a widely used and well-tolerated medication for the therapy of diabetes, is capable of effectively removing these tissues."

Specifically, the scientists discovered that metformin-pretreated melanoma control tissues were particularly delicate to modifications to their metabolism through the initial of AMPK.

In fact, metformin therapy led to the death of melanoma control tissues. In contrast, therapy of more separated melanoma tissues with metformin only caught the cells' growth.
"As the melanoma control tissues signify the root of pancreatic melanoma, their annihilation by re-training their metabolism with metformin along with the slowing down of the growth of more separated tissues should result in tumor regression and long-term, progression-free success," Heeschen said.

The scientists generated information to support this idea when they handled immunocompromised rats inserted with a different set of patient-derived tumours with a variety of metformin and gemcitabine, the conventional chemotherapeutic strategy to pancreatic melanoma.

They discovered that the therapy led to reduced tumor problem and the avoidance of backslide as compared with therapy with either medication alone.

"Intriguingly, in all tumours handled with metformin to date, backslide of disease was effectively avoided and there were no recognizable side effects," Heeschen said.

He considers that examining metformin in pancreatic melanoma is ready for scientific studies.

The pancreatic research team is currently looking forward to outcomes of a study that tested metformin as a maintenance therapy in sufferers with advanced pancreatic melanoma. Although the reasoning for these studies was based on retrospective information, Heeschen said given these new results he wants that this therapy strategy would be highly effective.

"Pending final outcomes of these studies, an important factor for the future will be to examine if all sufferers react to metformin or whether some sufferers, due to unique inherited modifications, may not react to this metabolic re-training," he said.

Read more